All In Biotech

Drug Trial Radar · NCT05364671

Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients

Multicenter Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients

Last checked: Nov 19, 2026Latest source record: Jan 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 771 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

771

Actual

Start

Apr 29, 2022

Primary completion

Aug 18, 2023

Study completion Aug 18, 2023

Sponsor

Lead sponsor
Materia Medica HoldingIndustry
Sponsor type
Industry
First posted
May 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multicenter double-blind placebo-controlled parallel-group randomized clinical trial of efficacy and safety of Raphamin in the treatment of coronavirus disease 2019 in outpatients.

Conditions

  • Coronavirus Disease 2019 (COVID-19)

Interventions

  • RaphaminDrug

    Tablet for oral use. The drug is administered not during meals. The tablet should be held in mouth until complete dissolution. On the first day, 8 tablets should be administered using the following regimen: 1 tablet every 30 minutes in the first 2 hours (5 tablets in total within 2 hours), then additionally one tablet 3 times with regular time intervals. From day 2 onwards, 1 tablet taken 3 times daily. The treatment period is 5 days.

  • PlaceboDrug

    Tablet for oral use. The drug is administered not during meals. The tablet should be held in mouth until complete dissolution. Placebo is administered according to the Raphamin regimen.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With COVID-19 Progression to a More Severe FormTime frame: 28 days

Locations

36 sites in 1 country. Site status is shown where the registry gives one.

  • Belgorod State National Research University, Department of Hospital Therapy

    Belgorod, Russia

  • Ivanovo clinical hospital named after Kuvaevs/Polyclinic #10

    Ivanovo, Russia

  • Kazan State Medical University, Department of Propedeutics of Internal Diseases named after prof. S.S. Zimnitsky

    Kazan', Russia

  • Kazan State Medical University/Department of Infectious Diseases

    Kazan', Russia

  • Kirov State Medical University, Hospital Therapy Department

    Kirov, Russia

  • Kuban State Medical University, Infectious Diseases and Phthisiopulmonology

    Krasnodar, Russia

  • Clinical hospital "RZD-Medicine" of the city of Nizhny Novgorod

    Nizhny Novgorod, Russia

  • City Clinical Hospital # 2

    Novosibirsk, Russia

  • Clinical Hospital # 4

    Penza, Russia

  • LLC "Professor's Clinic"

    Perm, Russia

  • LLC "Ultrasound Clinic 4D"

    Pyatigorsk, Russia

  • Ryazan State Medical University named after Academician I.P. Pavlova

    Ryazan, Russia

  • LLC "BioTechService"

    Saint Petersburg, Russia

  • City clinic # 44

    Saint Petersburg, Russia

  • City Polyclinic # 25 of the Nevsky District

    Saint Petersburg, Russia

  • LLC "Energy of Health"

    Saint Petersburg, Russia

  • LLC "Strategic medical systems"

    Saint Petersburg, Russia

  • Llc "Medical Clinic"

    Saint Petersburg, Russia

  • LLC "Research Center Eco-safety"

    Saint Petersburg, Russia

  • JSC "North-West Center for Evidence-Based Medicine"

    Saint Petersburg, Russia

  • LLC "Clinic Zvezdnaya"

    Saint Petersburg, Russia

  • City Polyclinic # 43

    Saint Petersburg, Russia

  • Lomonosov Interdistrict Hospital named after I.N. Yudchenko

    Saint Petersburg, Russia

  • City Intercession Hospital

    Saint Petersburg, Russia

  • LLC "Meili"

    Saint Petersburg, Russia

  • City polyclinic # 74

    Saint Petersburg, Russia

  • Samara City Hospital # 4

    Samara, Russia

  • LLC "Center for DNA Research"

    Saratov, Russia

  • Saratov State Medical University named after V. I. Razumovsky

    Saratov, Russia

  • LLC "Scientific Medical Center for General Therapy and Pharmacology"

    Stavropol, Russia

  • Tver State Medical University

    Tver', Russia

  • Bashkir State Medical University, Internal Medicine Department

    Ufa, Russia

  • Voronezh Regional Clinical Hospital # 1

    Voronezh, Russia

  • Central city hospital

    Yaroslavl, Russia

  • LLC "Medical Center for Diagnostics and Prevention Plus"

    Yaroslavl, Russia

  • Central city hospital # 7

    Yekaterinburg, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.